Overview

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Status:
Recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Phase:
Phase 3
Details
Lead Sponsor:
Intellia Therapeutics
Collaborator:
Regeneron Pharmaceuticals